T2 and SeptiCyte RAPID Duration Project

Launched by THE UNIVERSITY OF QUEENSLAND · Mar 24, 2021

Keywords

ClinConnect Summary

The T2 and SeptiCyte RAPID Duration Project is a clinical trial focused on understanding how long bacteria stay in the blood during an infection. This is important because if the germs linger for a long time, it may mean that doctors need to change the antibiotics being used. On the other hand, if the bacteria are only in the blood for a short period, doctors might feel confident switching to oral antibiotics, which could allow patients to leave the hospital sooner. The trial is testing two new technologies to see how well they can help measure this duration and predict patient outcomes.

To participate in this study, patients must have a confirmed bloodstream infection caused by specific types of bacteria or fungi. Unfortunately, those receiving palliative care, unable to provide consent, or with mixed infections will not be eligible. Participants can expect to undergo tests using the new technologies being evaluated, which could provide valuable information for their treatment. This trial is currently recruiting patients aged 65 to 74, and it aims to improve how doctors manage bloodstream infections, ultimately enhancing patient care.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients who have proven bloodstream infection with any T2-on panel pathogen (Enterococcus faecium, S. aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, Escherichia coli and Candida spp.)
• Exclusion Criteria:
• • Palliative care approach
• • Failure to give written informed consent (by patient or their legal representative)
• • Polymicrobial index blood culture